Annual SG&A
$12.83 M
-$2.46 M-16.07%
01 December 2023
Summary:
NovaBay Pharmaceuticals annual selling, general & administrative expenses is currently $12.83 million, with the most recent change of -$2.46 million (-16.07%) on 01 December 2023. During the last 3 years, it has fallen by -$2.50 million (-16.32%). NBY annual SG&A is now -42.59% below its all-time high of $22.35 million, reached on 31 December 2017.NBY Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.65 M
+$14.00 K+0.53%
01 September 2024
Summary:
NovaBay Pharmaceuticals quarterly selling, general & administrative expenses is currently $2.65 million, with the most recent change of +$14.00 thousand (+0.53%) on 01 September 2024. Over the past year, it has dropped by -$2.12 million (-44.46%). NBY quarterly SG&A is now -61.19% below its all-time high of $6.83 million, reached on 31 March 2017.NBY Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$715.57 M
-$16.57 M-2.37%
01 September 2024
Summary:
NovaBay Pharmaceuticals TTM selling, general & administrative expenses is currently -$715.57 million, with the most recent change of -$16.57 million (-2.37%) on 01 September 2024. Over the past year, it has dropped by -$728.39 million (-5677.28%). NBY TTM SG&A is now -9088.05% below its all-time high of $22.69 million, reached on 30 September 2017.NBY TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBY Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -44.5% | -5677.3% |
| 3 y3 years | -16.3% | -45.5% | -4896.0% |
| 5 y5 years | -8.9% | -20.4% | -5183.2% |
NBY Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -16.3% | at low | -45.5% | +12.5% | -27.6% | at low |
| 5 y | 5 years | -16.3% | +6.0% | -45.5% | +12.5% | -46.4% | at low |
| alltime | all time | -42.6% | +693.4% | -61.2% | +159.6% | -9088.0% | at low |
NovaBay Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.65 M(+0.5%) | $13.40 M(+2.2%) |
| June 2024 | - | $2.64 M(-21.2%) | $13.11 M(-1.0%) |
| Mar 2024 | - | $3.35 M(-29.9%) | $13.24 M(+3.2%) |
| Dec 2023 | $12.83 M(-16.1%) | $4.77 M(+102.5%) | $12.83 M(+3.2%) |
| Sept 2023 | - | $2.36 M(-14.9%) | $12.44 M(-3.4%) |
| June 2023 | - | $2.77 M(-5.7%) | $12.87 M(-8.4%) |
| Mar 2023 | - | $2.94 M(-33.0%) | $14.05 M(-8.1%) |
| Dec 2022 | $15.29 M(-0.3%) | $4.38 M(+56.9%) | $15.29 M(-3.1%) |
| Sept 2022 | - | $2.79 M(-29.3%) | $15.77 M(-6.2%) |
| June 2022 | - | $3.95 M(-5.2%) | $16.81 M(+3.7%) |
| Mar 2022 | - | $4.17 M(-14.3%) | $16.22 M(+8.7%) |
| Dec 2021 | $15.33 M(+26.7%) | $4.86 M(+26.9%) | $14.92 M(+16.1%) |
| Sept 2021 | - | $3.83 M(+14.1%) | $12.85 M(+2.1%) |
| June 2021 | - | $3.36 M(+17.1%) | $12.59 M(+3.8%) |
| Mar 2021 | - | $2.87 M(+2.5%) | $12.13 M(+0.2%) |
| Dec 2020 | $12.11 M(-14.0%) | $2.80 M(-21.7%) | $12.11 M(-4.2%) |
| Sept 2020 | - | $3.57 M(+23.1%) | $12.64 M(+5.8%) |
| June 2020 | - | $2.90 M(+2.2%) | $11.95 M(+1.4%) |
| Mar 2020 | - | $2.84 M(-14.8%) | $11.78 M(-16.3%) |
| Dec 2019 | $14.08 M(-24.4%) | $3.33 M(+15.8%) | $14.08 M(-8.8%) |
| Sept 2019 | - | $2.88 M(+5.3%) | $15.43 M(-9.9%) |
| June 2019 | - | $2.73 M(-46.8%) | $17.13 M(-8.6%) |
| Mar 2019 | - | $5.14 M(+9.6%) | $18.73 M(+0.6%) |
| Dec 2018 | $18.62 M(-16.7%) | $4.69 M(+2.5%) | $18.62 M(-0.6%) |
| Sept 2018 | - | $4.57 M(+5.5%) | $18.73 M(-5.2%) |
| June 2018 | - | $4.34 M(-13.6%) | $19.76 M(-3.8%) |
| Mar 2018 | - | $5.02 M(+4.5%) | $20.54 M(-8.1%) |
| Dec 2017 | $22.35 M(+17.3%) | $4.80 M(-14.4%) | $22.35 M(-1.5%) |
| Sept 2017 | - | $5.61 M(+9.7%) | $22.69 M(+3.1%) |
| June 2017 | - | $5.11 M(-25.1%) | $22.01 M(+4.6%) |
| Mar 2017 | - | $6.83 M(+32.8%) | $21.05 M(+10.5%) |
| Dec 2016 | $19.04 M(+2.8%) | $5.14 M(+4.3%) | $19.04 M(-4.7%) |
| Sept 2016 | - | $4.93 M(+18.9%) | $19.99 M(+1.1%) |
| June 2016 | - | $4.15 M(-14.1%) | $19.78 M(-0.6%) |
| Mar 2016 | - | $4.83 M(-20.7%) | $19.89 M(+7.3%) |
| Dec 2015 | $18.53 M | $6.09 M(+29.1%) | $18.53 M(+22.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $4.72 M(+10.8%) | $15.16 M(+22.7%) |
| June 2015 | - | $4.26 M(+22.8%) | $12.35 M(+26.7%) |
| Mar 2015 | - | $3.47 M(+27.7%) | $9.75 M(+22.0%) |
| Dec 2014 | $7.99 M(+26.0%) | $2.72 M(+42.1%) | $7.99 M(+22.3%) |
| Sept 2014 | - | $1.91 M(+15.6%) | $6.53 M(+6.3%) |
| June 2014 | - | $1.65 M(-3.2%) | $6.14 M(-6.0%) |
| Mar 2014 | - | $1.71 M(+35.7%) | $6.54 M(+2.3%) |
| Dec 2013 | $6.34 M(+6.1%) | $1.26 M(-17.4%) | $6.39 M(-8.2%) |
| Sept 2013 | - | $1.52 M(-25.4%) | $6.96 M(+4.4%) |
| June 2013 | - | $2.04 M(+31.1%) | $6.67 M(+11.3%) |
| Mar 2013 | - | $1.56 M(-14.7%) | $5.99 M(+0.3%) |
| Dec 2012 | $5.97 M(+10.0%) | $1.83 M(+48.1%) | $5.97 M(+5.8%) |
| Sept 2012 | - | $1.23 M(-9.8%) | $5.64 M(+2.5%) |
| June 2012 | - | $1.37 M(-11.2%) | $5.50 M(+0.9%) |
| Mar 2012 | - | $1.54 M(+2.8%) | $5.46 M(+0.5%) |
| Dec 2011 | $5.43 M(-4.0%) | $1.50 M(+36.6%) | $5.43 M(+8.2%) |
| Sept 2011 | - | $1.10 M(-16.8%) | $5.02 M(-7.2%) |
| June 2011 | - | $1.32 M(-13.0%) | $5.41 M(-5.1%) |
| Mar 2011 | - | $1.51 M(+39.4%) | $5.70 M(+0.8%) |
| Dec 2010 | $5.65 M(+0.8%) | $1.09 M(-26.9%) | $5.65 M(-7.3%) |
| Sept 2010 | - | $1.49 M(-7.7%) | $6.10 M(+3.0%) |
| June 2010 | - | $1.61 M(+9.7%) | $5.92 M(+7.6%) |
| Mar 2010 | - | $1.47 M(-3.9%) | $5.50 M(-2.0%) |
| Dec 2009 | $5.61 M(-0.5%) | $1.53 M(+16.8%) | $5.61 M(+9.1%) |
| Sept 2009 | - | $1.31 M(+9.9%) | $5.14 M(-4.4%) |
| June 2009 | - | $1.19 M(-24.6%) | $5.38 M(-6.7%) |
| Mar 2009 | - | $1.58 M(+48.8%) | $5.76 M(-1.8%) |
| Dec 2008 | $5.64 M(+29.0%) | $1.06 M(-31.3%) | $5.86 M(-3.0%) |
| Sept 2008 | - | $1.54 M(-2.0%) | $6.05 M(+9.5%) |
| June 2008 | - | $1.57 M(-6.5%) | $5.52 M(+10.1%) |
| Mar 2008 | - | $1.68 M(+35.5%) | $5.02 M(+14.9%) |
| Dec 2007 | $4.37 M(+47.0%) | $1.24 M(+21.7%) | $4.37 M(+39.8%) |
| Sept 2007 | - | $1.02 M(-4.5%) | $3.13 M(+48.5%) |
| June 2007 | - | $1.07 M(+3.3%) | $2.10 M(+103.3%) |
| Mar 2007 | - | $1.03 M | $1.03 M |
| Dec 2006 | $2.97 M(+83.8%) | - | - |
| Dec 2005 | $1.62 M | - | - |
FAQ
- What is NovaBay Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly SG&A year-on-year change?
- What is NovaBay Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals TTM SG&A year-on-year change?
What is NovaBay Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of NBY is $12.83 M
What is the all time high annual SG&A for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high annual selling, general & administrative expenses is $22.35 M
What is NovaBay Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of NBY is $2.65 M
What is the all time high quarterly SG&A for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $6.83 M
What is NovaBay Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, NBY quarterly selling, general & administrative expenses has changed by -$2.12 M (-44.46%)
What is NovaBay Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of NBY is -$715.57 M
What is the all time high TTM SG&A for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high TTM selling, general & administrative expenses is $22.69 M
What is NovaBay Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, NBY TTM selling, general & administrative expenses has changed by -$728.39 M (-5677.28%)